Monthly Update26 Aug 2025, 03:55 pm
Shilpa Medicare's Transformative Innovation in FY25: A 38% Annual Report
AI Summary
Shilpa Medicare Ltd. has shown remarkable progress in FY25 across its core business verticals of APIs, Formulations, and Biosimilars. The API division is breaking new ground in developing high-value molecules, with a focus on complex APls in Oncology and new technologies like GLP-1, Peptide, and Polymers. The Formulations division has redefined treatment paradigms with several first-to-market innovations, and the Biosimilars division is gaining momentum with Adalimumab demonstrating strong market performance. The company is also expanding its global footprint and advancing global biopharma through end-to-end CDMO excellence.
Key Highlights
- Shilpa Medicare's API division continues to innovate, developing complex molecules and advanced synthesis technologies.
- The Formulations division has made significant strides in patient-centric solutions, with several first-to-market innovations.
- The Biosimilars division is gaining momentum, with Adalimumab demonstrating strong market performance and Phase III clinical trials initiated for a second biosimilar product.
- Shilpa Medicare is expanding its global footprint, strengthening its footprint in emerging markets, and advancing global biopharma through end-to-end CDMO excellence.